StockData

Burning Rock Biotech vs Castle Biosciences

BNR and CSTL side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How BNR and CSTL compare

Castle Biosciences grew revenue faster over the last twelve months (9.8% versus 4.6% for Burning Rock Biotech).

Castle Biosciences keeps more of each dollar of sales as profit, with a net margin of −6.1% compared with −10.3% at Burning Rock Biotech.

Castle Biosciences scores higher on the StockData Score (11 against 5 for Burning Rock Biotech), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricBNRCSTL
Size and price
Market cap–$1.0B
Share price$13.29$33.79
Change, 1 year8.8%−3.0%
Change, 5 years−92.2%−28.9%
Beta (5Y)1.731.38
Employees667883
StockData Score
Total score511 (better)
Valuation score02 (better)
Growth score12 (better)
Performance score23 (better)
Health score24 (better)
Dividend score00
Valuation
P/S–2.7×
P/B–2.2×
P/FCF–260×
FCF yield–0.38%
Fair value–$34.71
Margin of safety–2.6%
Growth
Revenue growth (TTM)4.6%9.8% (better)
Revenue growth, 5Y average4.6%40.6% (better)
Profitability
Gross margin74.7%77.1% (better)
Operating margin−10.2%−7.4% (better)
Net margin−10.3%−6.1% (better)
FCF margin−6.2%1.1% (better)
Return on equity−9.9%−4.9% (better)
Return on invested capital−72.5%−11.1% (better)
Financial health
Debt / equity0.00 (better)0.02
Interest coverage–−51.2×
Current ratio2.995.28 (better)
Altman Z-score–6.63
Piotroski F-score5 (better)4
Dividends and buybacks
Dividend yield–0.00%
Years of dividend growth–0
Shareholder yield–0.00%
Ownership
Held by institutions1.8%89.5%
Held by insiders19.0%1.9%
Insider net buying, 12 months$11.6M (better)−$18.3M
Short interest, % of float–7.0%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.